Virtu Financial LLC Navidea Biopharmaceuticals, Inc. Transaction History

Virtu Financial LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.07 - $0.12 $23,314 - $39,968	333,069 New	333,069 $30,000
Q1 2023 May 01, 2023	SELL	$0.24 - $0.34 $4,164 - $5,900	-17,353 Reduced 51.56%	16,301 $4,000
Q4 2022 Feb 15, 2023	SELL	$0.18 - $0.3 $820 - $1,367	-4,557 Reduced 11.93%	33,654 $7,000
Q3 2022 Nov 07, 2022	BUY	$0.24 - $0.71 $9,170 - $27,129	38,211 New	38,211 $10,000
Q2 2022 Aug 09, 2022	SELL	$0.63 - $1.1 $9,124 - $15,931	-14,483 Closed	0 $0
Q1 2022 May 17, 2022	SELL	$0.72 - $1.2 $7,722 - $12,871	-10,726 Reduced 42.55%	14,483 $11,000
Q4 2021 Feb 17, 2022	BUY	$1.0 - $1.82 $25,209 - $45,880	25,209 New	25,209 $25,000
Q3 2020 Dec 11, 2020	SELL	$2.69 - $4.95 $47,306 - $87,050	-17,586 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$0.7 - $4.16 $12,310 - $73,157	17,586 New	17,586 $69,000
Q4 2019 Feb 04, 2020	SELL	$0.65 - $1.26 $12,357 - $23,953	-19,011 Closed	0 $0
Q3 2019 Nov 20, 2019	SELL	$0.5 - $0.91 $22,873 - $41,629	-45,747 Reduced 70.64%	19,011 $13,000
Q2 2019 Aug 13, 2019	BUY	$0.62 - $3.6 $40,149 - $233,128	64,758 New	64,758 $41,000

10.4K

Ticker NAVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,150,900
Description
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expr...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.